However, given the widespread use of SGLT2 inhibitors in patients with T2DM due to their established cardiorenal benefits, it may be challenging to isolate and evaluate the effects of tirzepatide in the absence of concomitant SGLT2 inhibitor use. Here, SLC5A2 is linked to type 2 diabetes mellitus.